These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

144 related articles for article (PubMed ID: 11957260)

  • 1. Expression of oestrogen and progesterone receptors, Ki-67, p53 and BCL-2 proteins, cathepsin D, urokinase plasminogen activator and urokinase plasminogen activator-receptors in carcinomas of the female breast in an African population.
    Mbonde MP; Amir H; Akslen LA; Kitinya JN
    East Afr Med J; 2001 Jul; 78(7):360-5. PubMed ID: 11957260
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Cathepsin-D, urokinase plasminogen activator and type-1 plasminogen activator inhibitor in early breast cancer: an immunohistochemical study of prognostic value and relations to tenascin-C and other factors.
    Jahkola T; Toivonen T; von Smitten K; Virtanen I; Wasenius VM; Blomqvist C
    Br J Cancer; 1999 Apr; 80(1-2):167-74. PubMed ID: 10389993
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Prognostic value of p53 and urokinase-type plasminogen activator in node-negative human breast cancers.
    Peyrat JP; Vanlemmens L; Fournier J; Huet G; Révillion F; Bonneterre J
    Clin Cancer Res; 1998 Jan; 4(1):189-96. PubMed ID: 9516970
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cytological evaluation of biological prognostic markers from primary breast carcinomas.
    Makris A; Allred DC; Powles TJ; Dowsett M; Fernando IN; Trott PA; Ashley SE; Ormerod MG; Titley JC; Osborne CK
    Breast Cancer Res Treat; 1997 May; 44(1):65-74. PubMed ID: 9164679
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Urokinase-type plasminogen activator and its inhibitor PAI-1: predictors of poor response to tamoxifen therapy in recurrent breast cancer.
    Foekens JA; Look MP; Peters HA; van Putten WL; Portengen H; Klijn JG
    J Natl Cancer Inst; 1995 May; 87(10):751-6. PubMed ID: 7563153
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Plasminogen activator inhibitor-1 and prognosis in primary breast cancer.
    Foekens JA; Schmitt M; van Putten WL; Peters HA; Kramer MD; Jänicke F; Klijn JG
    J Clin Oncol; 1994 Aug; 12(8):1648-58. PubMed ID: 8040677
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Expression of estrogen and progesterone receptors in carcinomas of the female breast in Tanzania.
    Mbonde MP; Amir H; Schwartz-Albiez R; Akslen LA; Kitinya JN
    Oncol Rep; 2000; 7(2):277-83. PubMed ID: 10671671
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Value of immunohistochemical determination of receptors, tissue proteases, tumor suppressor proteins and proliferation markers as prognostic indicators in primary breast carcinoma].
    Göhring UJ; Scharl A; Ahr A
    Geburtshilfe Frauenheilkd; 1996 Apr; 56(4):177-83. PubMed ID: 8682282
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Differences in oestrogen and progesterone receptors, HER-2, p53 expression and proliferation in ductal breast cancers in relation to histopathological grade.
    Zasławski R; Surowiak P; Paluchowski P; Dziegiel P; Maciejczyk A; Pudełko M; Wojnar A; Zabel M
    Folia Morphol (Warsz); 2005 Feb; 64(1):9-15. PubMed ID: 15832264
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Urokinase plasminogen activator system gene expression is increased in human breast carcinoma and its bone metastases--a comparison of normal breast tissue, non-invasive and invasive carcinoma and osseous metastases.
    Fisher JL; Field CL; Zhou H; Harris TL; Henderson MA; Choong PF
    Breast Cancer Res Treat; 2000 May; 61(1):1-12. PubMed ID: 10930085
    [TBL] [Abstract][Full Text] [Related]  

  • 11. p53 protein expression and oestrogen and progesterone receptor status in invasive ductal breast carcinomas.
    Ioakim-Liossi A; Karakitsos P; Markopoulos C; Aroni K; Athanassiadou P; Delivelioti K; Athanassiades P; Vaiopoulos G
    Cytopathology; 2001 Jun; 12(3):197-202. PubMed ID: 11380561
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Quantitative changes in cytological molecular markers during primary medical treatment of breast cancer: a pilot study.
    Makris A; Powles TJ; Allred DC; Ashley SE; Trott PA; Ormerod MG; Titley JC; Dowsett M
    Breast Cancer Res Treat; 1999 Jan; 53(1):51-9. PubMed ID: 10206072
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Bcl-2 expression on fine-needle aspirates from primary breast carcinoma: correlation with other biologic factors.
    Bozzetti C; Nizzoli R; Naldi N; Guazzi A; Camisa R; Bella MA; Cocconi G
    Cancer; 1999 Aug; 87(4):224-30. PubMed ID: 10455211
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Positive immunohistochemical expression of bcl-2 in hormone-independent breast carcinomas is associated with a greater lymph node involvement and poor outcome.
    Ruibal Á; Aguiar P; Del Río MC; Menéndez P; Arias JI; Herranz M
    Med Oncol; 2014 Aug; 31(8):105. PubMed ID: 25008065
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Clinical relevance of urokinase-type plasminogen activator, its receptor, and its inhibitor type 1 in endometrial cancer.
    Tecimer C; Doering DL; Goldsmith LJ; Meyer JS; Abdulhay G; Wittliff JL
    Gynecol Oncol; 2001 Jan; 80(1):48-55. PubMed ID: 11136569
    [TBL] [Abstract][Full Text] [Related]  

  • 16. p53 protein accumulation predicts poor response to tamoxifen therapy of patients with recurrent breast cancer.
    Berns EM; Klijn JG; van Putten WL; de Witte HH; Look MP; Meijer-van Gelder ME; Willman K; Portengen H; Benraad TJ; Foekens JA
    J Clin Oncol; 1998 Jan; 16(1):121-7. PubMed ID: 9440732
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Multiple expression patterns of biopathological markers in primary invasive breast carcinoma: a useful tool for elucidating its biological behaviour.
    Ceccarelli C; Santini D; Chieco P; Taffurelli M; Marrano D; Mancini AM
    Ann Oncol; 1995 Mar; 6(3):275-82. PubMed ID: 7612493
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Apocrine carcinoma as triple-negative breast cancer: novel definition of apocrine-type carcinoma as estrogen/progesterone receptor-negative and androgen receptor-positive invasive ductal carcinoma.
    Tsutsumi Y
    Jpn J Clin Oncol; 2012 May; 42(5):375-86. PubMed ID: 22450930
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Tumor growth fraction, expression of estrogen and progesterone receptors, p53, bcl-2 and cathepsin D activity in primary ductal invasive breast carcinoma and their axillary lymph node metastases.
    Kristek J; Dmitrović B; Kurbel S; Sakić K; Krajinović Z; Blazicević V; Has B; Marjanović K
    Coll Antropol; 2007 Dec; 31(4):1043-7. PubMed ID: 18217456
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Association between tumor size and immunohistochemical expression of Ki-67, p53 and BCL2 in a node-negative breast cancer population selected from a breast cancer screening program.
    González-Sistal A; Sánchez AB; Del Rio MC; Arias JI; Herranz M; Ruibal A
    Anticancer Res; 2014 Jan; 34(1):269-73. PubMed ID: 24403473
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.